The inspiration behind MyCardium AI was the culmination of a number of influences, including the COVID-19 pandemic
The inspiration behind MyCardium AI was the culmination of a number of influences, including the COVID-19 pandemic, changing workflow patterns and a genuine desire to change patient outcomes for the better.
The business is a UCL spin-out and was the brainchild of Professor James Moon, Professor Mark Westwood and Professor Charlotte Manisty, some of the world’s most eminent authorities on cardiology, who envisaged a future for AI in patient diagnosis and treatment and wanted to find a commercial route to take that forward. They shared that vision with long-time contact Antony Shimmin and MyCardium AI was born in April 2022.
MyCardium AI recently moved into an expanded private office space at Liverpool Science Park, having originally joined the Sciontec community in our co-working space at The Spine.
Antony Shimmin, Chief Operating Officer at MyCardium AI, explains:
“From day one, Sciontec helped us to find a place to work within The Spine and I will be forever grateful to head of property George Barclay for his support and flexibility. By January 2023 we were beginning to scale-up and, keen to remain with Sciontec, we moved into a four-person desk space at Liverpool Science Park in July of the same year.
“We quickly outgrew that space and Sciontec once again helped us to source a larger space within the same building and we are now in a 1,389 sq ft private office.”
The continued growth of MyCardium AI’s office space at Sciontec reflects the company’s ongoing commercial growth, with new products and services now being added to its original offer.
Antony explains:
“We began by using AI to review the results of cardiac MRI scans, which can capture key measurements. No matter how hard humans try, there will always be some inherent element of unconscious bias when they are evaluating results, but AI removes that.
“Our original plan was to deliver AI as a software service into hospitals, while pharmaceutical companies also use it for clinical trial follow-ups and it also helps to reduce the number of participants. We use medical experts to provide analysis.
“We were also successful in applying to the Innovate UK scale-up programme, which funds only 1% of applications, so we are relatively rare in that sense.”
The group has also launched a separate division, Guilford Street Labs, offering a full suite of diagnostic tools. On the company’s plans for the future,
Antony said:
“We now have 20 full time staff and 45 contractors working with us, and hopefully that will more than double in the coming years.
“Liverpool is a great place for us to be headquartered. It has a strong innovation ecosystem, with some very good people, and it feels like we are working towards a shared vision here in the city.”
